NCT05913960 Accelerated Intermittent Theta-Burst Stimulation Ameliorate Major Depressive Disorder by Regulating CAMKII Pathway
| NCT ID | NCT05913960 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Condition | Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-02-09 |
| Primary Completion | 2024-03-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2023-02-09 with a primary completion date of 2024-03-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Major depressive disorder(MDD) is a complex and heterogeneous mental disorder. Repeated transcranial magnetic stimulation (rTMS), as a non-invasive neuroregulatory technique, has shown a promising function in the treatment of depression. Theta-burst transcranial magnetic stimulation (TBS) model significantly shortened the duration of physical therapy treatment, and iTBS under the accelerated model (The latter is referred to as aiTBS)showed promising therapeutic effect. However, whether aiTBS has a better and faster curative effect in the first untreated or recurrent unmedicated MDD patients and the mechanism of its alleviation of depressive symptoms remains unclarified. This project intends to verify changes in CAMKII levels, CAMKII molecules and GABA receptors in brain-derived exosomes in normal controls and patients who received sham, aiTBS and high-frequency (10Hz) stimulation respectively. Neuroimaging and TMS-EEG were used to pinpoint the target of stimulation and to record the changes of brain waves before and after treatment in real time. To clarify the neurobiological mechanism of aiTBS rapidly improving depression, and to provide a new strong evidence for clinical transcranial magnetic stimulation for accurate treatment of MDD patients.
Eligibility Criteria
Inclusion Criteria: * Sign a written informed consent to participate in the trial and receive treatment; * Major depressive disorder diagnosis; * Hamilton depression scale (HAMD - 24) 24 total score 20 points or more; * First episode or recurrence of depression patients, not taking psychiatric drugs; * The han nationality, right-handed; * Junior high school or above; Exclusion Criteria: * Other organic mental disorders and mental retardation and other severe mental disorders; * Infection, trauma, and autoimmune diseases or other possible interference test evaluation of disease; * Alcohol and drug dependence or is being treated for a hormone drugs patients; * Craniocerebral injury; * Seizure or a family history of epilepsy; * Pregnancy and lactation women; * All landowners had a metal and MRI contraindications or MRI examination revealed abnormal brain structure.
Frequently Asked Questions
Who can join the NCT05913960 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 45 Years, studying Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05913960 currently recruiting?
Yes, NCT05913960 is actively recruiting participants. Visit ClinicalTrials.gov or contact First Affiliated Hospital of Zhejiang University to inquire about joining.
Where is the NCT05913960 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT05913960 clinical trial?
NCT05913960 is sponsored by First Affiliated Hospital of Zhejiang University. The trial plans to enroll 90 participants.